In a landscape dominated by tariff threats and diplomatic posturing, a quiet but vital argument emerges from Beijing: the fentanyl crisis is not a weapon of statecraft, but a shared public health emergency that demands functional cooperation regardless of political winds. Zichen Wang's analysis cuts through the noise of the current trade standoff to reveal a stark reality often ignored in Washington and Beijing alike—that both nations are simultaneously sites of production, transit, and consumption, and that blaming one side for the other's domestic failures is a strategic dead end.
Reframing the Crisis
Wang, a professor at Peking University, challenges the prevailing narrative that frames the opioid epidemic solely as a result of Chinese negligence or malice. He writes, "for both China and the United States, there is no justification for either rhetoric or policy to hold the other responsible for the fentanyl-related predicament, whether it stems from negligence or is perceived as intentional." This is a crucial pivot. By decoupling the drug crisis from the broader trade war, Wang argues that the solution lies in "functional cooperation"—the kind of technical, agency-to-agency collaboration that historically survives even when high-level politics freeze.
The piece is particularly effective in dismantling the idea that China is merely a passive supplier. Wang notes that the illicit drug market has a "unique resilience that is set to survive national and international control efforts," suggesting that punitive tariffs are a blunt instrument ill-suited for a complex, adaptive criminal ecosystem. He points out that since 2017, fentanyl has become a "prominent issue in Sino–American relations," often used by the executive branch as a justification for levying additional tariffs. However, he argues this linkage is flawed because it ignores the domestic roots of the crisis in the United States.
"The quality of the competition hinges on the degree of progress in finding effective solutions to the fentanyl/opioid challenge through domestic efforts and international cooperation."
Wang's framing here is sophisticated. He suggests that the "competition" between the two superpowers should not be about who can blame the other more effectively, but about who can demonstrate superior governance and public health outcomes. This reframes the issue from a zero-sum geopolitical game to a test of institutional competence. Critics might note, however, that this functionalist approach assumes a level of bureaucratic autonomy that may not exist when national security narratives are so deeply entrenched. If the White House views fentanyl primarily through the lens of economic leverage, technical working groups may struggle to gain traction.
The Human Cost and the "China Shock"
The article does not shy away from the human tragedy fueling these political tensions. Wang connects the rise in fentanyl deaths to the broader phenomenon of "deaths of despair" in the United States, citing economic literature that links trade policy shifts to increased mortality among working-age populations. He writes, "counties more exposed to the change in US trade policy exhibit relative increases in deaths of despair," highlighting how economic anxiety and drug addiction are often two sides of the same coin.
This context is vital. It reminds the reader that the push for tariffs is often a political response to real suffering, even if the policy prescription is misaligned with the problem. Wang acknowledges that narratives holding China responsible are "prolific and sustained," driven by a deep-seated sentiment among American elites. Yet, he insists that "China subordinates its counternarcotics cooperation to its geostrategic relations" is a misconception. He points to concrete data: following the 2023 summit, China banned the export of 55 precursor chemicals and took action against hundreds of citizens. As Wang puts it, "China expresses sympathy for the American people suffering from the fentanyl crisis... and remains open to continuing cooperation."
The author's argument gains strength by grounding the debate in the history of the International Narcotics Control Board and the specific regulatory steps China took in 2019, when it listed all fentanyl-related substances as controlled. This historical depth counters the amnesia often present in current political discourse. The article suggests that the "China Shock" narrative is a convenient political meme that obscures the reality of a global, multi-national supply chain that no single country can unilaterally police.
"In that sense, the ultimate winner is progress in humanity."
This concluding thought elevates the piece beyond mere policy analysis. It posits that the true measure of success in Sino-American relations is not the volume of trade or the height of tariff walls, but the ability of both nations to protect their citizens from a chemical threat that respects no borders. The argument is that "enhanced bilateral cooperation should be established as a standard practice," independent of "fluctuations in trade and other aspects of interactions."
Structural Hurdles and the Path Forward
Despite the compelling case for cooperation, Wang admits the structural challenges are immense. He notes that achieving synergies in counternarcotics is "profoundly challenging" because it requires expertise spanning social sciences, pharmacology, and law enforcement. He writes, "mastery of fundamentals in biological, biomedical, medicinal, medical, pharmacological, and pharmaceutical sciences is required for assessing validity behind descriptions."
This admission of complexity is refreshing. It serves as a warning against oversimplified solutions. The article suggests that while the 2025 tariff discussions may continue to link fentanyl to trade, the value of scientific exchange remains. "Regardless of how the 2025 tariff discussions progress, there continues to be value in fostering exchange in scientific knowledge on opioids and evidence-based cooperation," Wang concludes.
The piece effectively argues that the "China Shock" narrative is a distraction from the real work of managing synthetic opioids. By focusing on the technical and functional aspects of the crisis, Wang offers a roadmap for a more stable, if not entirely cooperative, relationship. The argument is that both societies must face the "salient fact that they are sites of production, transit, and consumption."
Bottom Line
Zichen Wang's strongest contribution is his insistence on separating the fentanyl crisis from the trade war, arguing that the human cost of addiction demands a functional response that transcends political rhetoric. The argument's greatest vulnerability lies in its reliance on bureaucratic rationality in an era where both governments are increasingly prone to using public health crises as geopolitical leverage. Readers should watch to see if the proposed "joint counternarcotics working group" can maintain its momentum as the 2025 tariff deadlines approach, or if the political pressure to link the two issues proves too great to ignore.